DexCom (NASDAQ:DXCM) PT Raised to $122.00 at Morgan Stanley
DexCom (NASDAQ:DXCM – Free Report) had its price objective raised by Morgan Stanley from $101.00 to $122.00 in a research note issued to investors on Monday morning, Benzinga reports. They currently have an equal weight rating on the medical device company’s stock. Several other research analysts have also recently weighed in on the stock. Leerink […]
United States Barryj Regan Leerink Partnrs Michael Jon Brown Robertw Baird Valley National Advisers Inc
Source: tickerreport.com